Metacrine, Inc.: management transactions · United States · SEC (Form 4)

About Metacrine, Inc.

Metacrine, Inc. is a U.S.-based biopharmaceutical company that was listed on the NASDAQ market in the United States (United States). The company was incorporated in 2014 and is headquartered in San Diego, California. From an equity-analysis perspective, Metacrine has historically been a clinical-stage biotech rather than a commercial pharma company, with a business model built around discovery, early development, and clinical testing of differentiated therapies for gastrointestinal and liver diseases. The company’s core scientific focus has centered on novel drug targets and mechanisms intended to address unmet needs in inflammatory and digestive disorders. In public filings, Metacrine described a pipeline built around FXR and HSD17β13-related programs, reflecting an emphasis on mechanistically differentiated approaches. Its most visible lead candidate in recent years was MET642, an orally delivered FXR agonist positioned for ulcerative colitis and described in company communications as Phase 2 ready. As is typical for development-stage biotech names, the investment case was driven less by current sales and more by clinical readouts, regulatory milestones, capital allocation, and optionality around strategic transactions. Commercially, Metacrine did not operate as a diversified product company with marketed drugs. Instead, its value proposition depended on the progress of its pipeline, the strength of its intellectual property, and the ability to attract partners or acquirers. This placed the company in a highly competitive segment of the biotechnology universe, where peers are often pursuing similar inflammatory bowel disease, immunology, or liver-disease opportunities. In that environment, differentiation typically comes from efficacy, tolerability, dosing convenience, and the likelihood of achieving clean regulatory and clinical data. Geographically, the company’s operations were primarily U.S.-based, anchored in San Diego, with a wholly owned Australian subsidiary created to support certain clinical activities. In recent corporate history, one of the key milestones was the announced all-stock merger agreement with Equillium in September 2022, which would have transferred MET642 as part of the transaction; that deal was later mutually terminated in December 2022. This sequence underscored Metacrine’s strategic focus on capital preservation and value realization through M&A or other corporate actions rather than a long runway to independent commercialization. For investors monitoring SEC Form 4 insider transactions, MTCR should be viewed as a NASDAQ-listed U.S. biotech with a development-stage profile, a San Diego footprint, and a history shaped by pipeline-specific catalysts, restructuring, and strategic alternatives. The company’s recent narrative has been more about asset value, transaction optionality, and insider activity than about traditional operating momentum.